Solta Updates on Liposonix Launch - Analyst Blog
14 Marzo 2012 - 10:10AM
Zacks
Aesthetic laser treatments provider Solta
Medical (SLTM) recently provided an update on the launch
of the recently approved second-generation LIPOSONIX system for
non-invasive waist circumference reduction.
The California-based company stated that most of its roughly 20
key opinion leaders (comprising leading plastic surgeons and
dermatologists), who received Liposonix systems as part of the
pre-launch trial in December 2011, have successfully tested and
purchased the product. Solta expects that the remaining key opinion
leaders evaluating the system will buy the product in March
2012.
The company also noted that it will be showcasing Liposonix
along with its other industry leading aesthetic solutions at the
American Academy of Dermatology meeting, scheduled to be held at
the San Diego Convention Center from March 17 to 19.
Solta acquired rights to the LIPOSONIX system (which uses
advanced non-invasive ultrasound energy to reduce abdominal fat)
through its acquisition of Medicis Technologies, a unit of
specialty pharmaceutical company Medicis Pharmaceutical
Corporation (MRX).
The company announced, in October 2011, that Medicis
Technologies has won the U.S. approval for the second-generation
LIPOSONIX system. The device was launched in January 2012.
The second-generation LIPOSONIX system offers a treatment area
which is 2.7 times larger (compared with its predecessor) for
faster treatment times and has better ergonomics and ease of use
for the physicians.
The LIPOSONIX system is not a replacement for liposuction
surgery but offers a non-surgical approach to reduce waist
circumference when diet and exercise are not enough. It is an
effective treatment with a proven safety profile.
Unlike other non-invasive fat reduction therapies, LIPOSONIX
permanently ablates the fat cells found under the skin with just a
single treatment procedure that takes about an hour. Studies have
shown an average waist circumference reduction of roughly 2.6 cm (1
inch) following one LIPOSONIX treatment.
LIPOSONIX is also cleared for marketing across Canada, European
Union and Japan. Based on the initial user response, Solta expects
to meet or exceed its sales target (of roughly $17 million) for the
second generation system in 2012.
Solta Medical develops and markets devices for aesthetic
applications and is a global leader in the medical aesthetics
market. Its leading brands for skin tightening and skin resurfacing
are Thermage (a non-invasive radiofrequency procedure for
tightening and contouring the skin) and Fraxel (a novel class of
skin rejuvenation therapy).
Solta derives its revenues primarily from the sale of its
systems, treatment tips and other consumables. The company competes
with Allergan Inc. (AGN), Syneron
Medical (ELOS), Cutera (CUTR) and
Palomar Medical Technologies (PMTI).
ALLERGAN INC (AGN): Free Stock Analysis Report
CUTERA INC (CUTR): Free Stock Analysis Report
SYNERON MED LTD (ELOS): Free Stock Analysis Report
MEDICIS PHARM-A (MRX): Free Stock Analysis Report
PALOMAR MED TEC (PMTI): Free Stock Analysis Report
SOLTA MEDICAL (SLTM): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Syneron Medical Ltd. - Ordinary Shares (NASDAQ:ELOS)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024